Corbus Pharmaceuticals Holdings, Inc. will host a virtual webcast on Monday, September 14, 2026, at 8:00 a.m. EDT to discuss topline data from the CANYON-1 Phase 1b clinical trial of CRB-913. The study evaluates the once-daily oral CB1 inverse agonist as an alternative obesity therapy beyond incretin-targeting treatments.
Evaluating CRB-913 in the Obesity Therapeutics Landscape
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) has scheduled a conference call on Monday, September 14, 2026. Management intends to review the primary dataset emerging from its Phase 1b trial known as CANYON-1 (NCT07310901).
The trial itself evaluates CRB-913, classified as a highly peripherally restricted oral CB1 inverse agonist. This mechanism offers an orthogonal approach to long-term weight management, positioning itself beyond the GLP-1 and incretin-targeting pathways. Joining the company management team as a guest speaker on the webcast is Dr. Harold Bays, an investigator for the study, who brings clinical experience from the Louisville Metabolic and Atherosclerosis Research Center.
The Bottom Line
- Event Timing: The virtual webcast takes place on Monday, September 14, 2026, at 8:00 a.m. EDT.
- Trial Parameters: CANYON-1 is a 16-week, double-blind, placebo-controlled, dose-ranging study encompassing 240 obese, non-diabetic adult participants across multiple U.S. sites.
- Dosing Architecture: The trial evaluates three active cohorts receiving 20 mg, 40 mg, and 60 mg doses once daily, alongside a placebo cohort randomized at a 1:1:1:1 ratio.
CANYON-1 Design and Dose Escalation Architecture
Understanding the exact parameters of the CANYON-1 trial provides vital context for Monday’s upcoming data readout. The study enrolled 240 participants at clinical sites across the United States. The trial structure incorporates a specific dose titration regimen.
All participants assigned to active treatment arms commenced dosing at 20 mg per day. From there, subjects titrated upward to either 40 mg per day or 60 mg per day, depending on their predetermined cohort assignments. The dosing phase ran for 12 weeks, followed by a four-week safety follow-up period.
| Trial Parameter | Clinical Specification |
|---|---|
| Study Identifier | NCT07310901 |
| Patient Population | 240 obese, non-diabetic adult participants |
| Active Dose Cohorts | 20 mg, 40 mg, and 60 mg QD (Once Daily) |
| Randomization Ratio | 1:1:1:1 (Active cohorts vs. Placebo) |
| Treatment Duration | 12 weeks dosing, followed by 4-week safety follow-up |
Clinical Leadership and Market Positioning
The inclusion of Dr. Harold Bays as a guest speaker underscores the clinical focus of the upcoming presentation. Dr. Bays serves as the Medical Director of the Louisville Metabolic and Atherosclerosis Research Center and Monroe Biomedical Research, and has acted as an investigator for more than 700 clinical trials. His academic and clinical background in obesity medicine—including originating the term “adiposopathy”—provides a rigorous scientific lens through which the CANYON-1 findings will be analyzed.
Corbus aims to demonstrate the potential of CRB-913 as a new therapeutic option for obesity.
Market Outlook and Registration Protocols
Investors wishing to access the live audio webcast must complete registration, where an archived replay will remain accessible following the conclusion of the event.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
